Stock comparison
IDEXX Laboratories
Eli Lilly
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
LLY
Eli Lilly
Market cap
$1T
Sector
Healthcare
Overall winner
Eli Lilly LLY
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | LLY | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 72B | IDXX |
| Benjamin Graham | 80A | 86A | LLY |
| Philip Fisher | 75B | 86A | LLY |
| Peter Lynch | 71B | 74B | LLY |
| Joel Greenblatt | 83C | 78C | IDXX |
| Charlie Munger | 87A | 85A | IDXX |
| Terry Smith | 84A | 77C | IDXX |
Side-by-side metrics
| Metric | IDXX | LLY |
|---|---|---|
| Market cap | $44.06B | $1T |
| P/E (TTM) | 39.0x | 36.6x |
| EV/EBIT | 31.6x | 34.1x |
| ROIC (TTM) | 40.66% | 32.06% |
| Gross margin | 62.05% | 83.51% |
| Net margin | 24.63% | 34.98% |
| Revenue CAGR 5y | 7.56% | 23.17% |
| EPS CAGR 5y | 10.79% | 40.81% |
| Debt / Equity | 0.7x | 1.4x |
| Dividend yield | 0.0% | 0.62% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Debt / Equity0.7xvs 1.4x+50%
- ROIC (TTM)40.66%vs 32.06%+21%
- EV/EBIT31.6xvs 34.1x+7%
LLY leads on
- Dividend yield0.62%vs 0.0%+100%
- Market cap$1Tvs $44.06B+96%
- EPS CAGR 5y40.81%vs 10.79%+74%
- Revenue CAGR 5y23.17%vs 7.56%+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.